Tag Archives | HCV

Rayno Biopharmaceutical Stocks: PCYC Buzz Drive Biotechs Higher

Rayno Mid-Caps Outperform Bloomberg Report Drives Biotechs Higher Pharmacyclics, Inc. (PCYC) is up $34, 16.2 % to $219 today on a Bloomberg report that the Company was up for sale with Johnson and Johnson (JNJ) and Novartis (NVS) as potential suitors. Although M&A is a major trend in healthcare there have not been any major […]

Continue Reading 0

Rayno Dx and Tools: 2015 Q1 Mid Quarter Update-FMI, CSII, HOLX, ALR

Bullish Trend Continues for Mid-Cap Growth Stocks The Life Science Tools and Clinical Diagnostics sector kept pace with major life science ETF performance. Major  ETFs (FBT,IBB,XBI) are up about 10% YTD and our top performers are up over 10%. We will provide an update of our  Clinical Diagnostics portfolio after all earnings reports are in. […]

Continue Reading 0

Biotech Stocks Rally With Broad Market-Energy A Loser

Energy Stocks Down-Biotech and Healthcare Stocks Are Leaders NASDAQ Up 1.30%     4787 After a few days in the doldrums biotech stocks rallied across the board escaping the drag of macro news. Healthcare and technology sectors were among the leaders of the day moving in the opposite direction from energy. There have been dual […]

Continue Reading

Biotech Stocks Hit By Profit Taking: Risk Off- GILD News…Update

2/4/15 After the Bell ECB Impasse with Greece Hits Market Near Close…….. NASDAQ 4221 Down 0.19% Oil Plunges 9% to $48.74 on Inventory Rise Biotech Stocks Try To Recover But Get Hit By ECB News At Close ETFs down about 1.6% , XBI Down 1.9%, XLV down 1.24% Gilead (GILD) closes at $98.43 above lows […]

Continue Reading

Biotech Stocks Are Apparently Immune to Risks of the Day: New Highs Again …Update 2

3:55 p FEDspeak confuses markets with S&P down 1.25% Too much money around too little yield=deflation concerns. Energy takes a big hit again down 4%. Biotechs off 2% and more. ——— Update 1/28 Technology outperforming biotech in mid-day trading AAPL and semiconductor stocks are leading the NASDAQ up today. Speculators in mid-cap biotech stocks are […]

Continue Reading